Notably, all CLL patients who lacked a detectable SARS-CoV-2-specific T cell response had seroconverted for SARS-CoV-2 IgG, while two of them had borderline levels of SARS-CoV-2-specific IgA. The gene discussed is CD79A; the disease is B-cell chronic lymphocytic leukemia.